Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Hyun Jee Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4029-8764; OpenAlex author ID A5100371192, A5122665727. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2021: 1 paper · 2022: 2 papers · 2023: 4 papers · 2024: 4 papers · 2025: 2 papers · 2026: 2 papers

Papers 15

  1. Adaptive Salvage Stereotactic Radiation for Locoregional Recurrence of Pancreatic Adenocarcinoma After Surgery. Last author DOI 10.1016/j.prro.2026.03.015↗
  2. Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas):… First author DOI 10.2196/84607↗
  3. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  4. The Role of MR Guided Radiation Therapy in Pancreatic Cancer Treatment. Last author DOI 10.1016/j.semradonc.2025.08.002↗
  5. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label… Co-author DOI 10.1016/j.radonc.2023.110064↗
  6. Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally … Co-author DOI 10.1016/j.radonc.2024.110473↗
  7. Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
  8. Patient With Post-operative Recurrent Pancreatic Cancer Treated With Cone Beam Computed Tomography-Guided Stereotactic Adaptive Radiotherapy: A Case Report. Last author DOI 10.7759/cureus.75284↗
  9. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Co-author DOI 10.1016/j.ijrobp.2022.07.015↗
  10. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable… Co-author DOI 10.1016/j.ijrobp.2023.05.023↗
  11. Knowledge-based adaptive planning quality assurance using dosimetric indicators for stereotactic adaptive radiotherapy for pancreatic cancer. Co-author DOI 10.1016/j.radonc.2023.109603↗
  12. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
  13. Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer. Co-author DOI 10.1016/j.radonc.2022.08.026↗
  14. The first reported case of a patient with pancreatic cancer treated with cone beam computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR). Co-author DOI 10.1186/s13014-022-02125-z↗
  15. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Last author DOI 10.1016/j.adro.2020.06.010↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lauren E. Henke · 9 shared papers, 2021–2026 · strength 1.47
  2. Alex T. Price · 6 shared papers, 2022–2026 · strength 1.03
  3. Shahed Nicolas Badiyan · 6 shared papers, 2022–2024 · strength 0.91
  4. Michael David Chuong · 4 shared papers, 2023–2025 · strength 0.82
  5. Alden D'Souza · 3 shared papers, 2024–2025 · strength 0.81
  6. Joshua P. Schiff · 4 shared papers, 2022–2024 · strength 0.64
  7. Ryan C Fields · 4 shared papers, 2021–2024 · strength 0.55
  8. David G DeNardo · 3 shared papers, 2023–2026 · strength 0.55
  9. Kian‐Huat Lim · 3 shared papers, 2023–2026 · strength 0.51
  10. Clifford Grant Robinson · 3 shared papers, 2022–2024 · strength 0.48
  11. Michael Frederick Bassetti · 3 shared papers, 2023–2025 · strength 0.46
  12. Farnoush Forghani · 2 shared papers, 2023–2024 · strength 0.41
  13. Parag Jitendra Parikh · 3 shared papers, 2023–2024 · strength 0.41
  14. William G. Hawkins · 3 shared papers, 2021–2023 · strength 0.38
  15. John Ng · 2 shared papers, 2023–2024 · strength 0.27
  16. Luca Boldrini · 2 shared papers, 2023–2024 · strength 0.27
  17. Kathryn Elizabeth Mittauer · 2 shared papers, 2023–2024 · strength 0.27
  18. Lorenzo Placidi · 2 shared papers, 2023–2024 · strength 0.27
  19. Adam Christopher Mueller · 2 shared papers, 2023–2024 · strength 0.27
  20. Lorraine Portelance · 2 shared papers, 2023–2024 · strength 0.27
  21. Bassem I. Zaki · 2 shared papers, 2023–2024 · strength 0.27
  22. Joseph Douglas Mancias · 2 shared papers, 2023–2024 · strength 0.27
  23. Percy P. Lee · 2 shared papers, 2023–2024 · strength 0.27
  24. Daniel A. Low · 2 shared papers, 2023–2024 · strength 0.27
  25. Michael Charles Roach · 2 shared papers, 2021–2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.